• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[分枝杆菌对氟喹诺酮类药物敏感性的体外测定]

[In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].

作者信息

Dailloux M, Petitpain N, Henry C, Weber M

机构信息

Laboratoire de Microbiologie, Centre Hospitalier Régional Universitaire, Nancy-Brabois, Vandoeuvre.

出版信息

Pathol Biol (Paris). 1989 May;37(5):346-9.

PMID:2780092
Abstract

In vitro activity of four fluorinated quinolones: pefloxacin, norfloxacin, ciprofloxacin, ofloxacin were determined against various clinical isolates of mycobacteria. The method of agar dilution was used, seventy strains of ten species were tested: Mycobacterium tuberculosis (25), Mycobacterium bovis (5), Mycobacterium africanum (2), BCG (5), Mycobacterium kansasii (6), Mycobacterium marinum (5), Mycobacterium avium (11), Mycobacterium xenopi (6), Mycobacterium chelonae (3), Mycobacterium fortuitum (2). Except for Mycobacterium avium and Mycobacterium chelonae (CMI 100% greater than 8 mg/l) fluorinated quinolones showed activity against tested mycobacteria (CMI 100% less than or equal to 8 mg/l). Ofloxacin and ciprofloxacin where found to be the most active. Their activity against the different strains of Mycobacterium tuberculosis was unrelated to their susceptibility or resistance to the antituberculous drugs.

摘要

测定了四种氟喹诺酮类药物

培氟沙星、诺氟沙星、环丙沙星、氧氟沙星对各种临床分离分枝杆菌的体外活性。采用琼脂稀释法,检测了十个菌种的70株菌:结核分枝杆菌(25株)、牛分枝杆菌(5株)、非洲分枝杆菌(2株)、卡介苗(5株)、堪萨斯分枝杆菌(6株)、海分枝杆菌(5株)、鸟分枝杆菌(11株)、偶发分枝杆菌(6株)、龟分枝杆菌(3株)、脓肿分枝杆菌(2株)。除鸟分枝杆菌和龟分枝杆菌(最低抑菌浓度100%大于8mg/l)外,氟喹诺酮类药物对受试分枝杆菌有活性(最低抑菌浓度100%小于或等于8mg/l)。发现氧氟沙星和环丙沙星活性最强。它们对不同结核分枝杆菌菌株的活性与其对抗结核药物的敏感性或耐药性无关。

相似文献

1
[In vitro determination of the sensitivity of mycobacteria to fluoroquinolones].[分枝杆菌对氟喹诺酮类药物敏感性的体外测定]
Pathol Biol (Paris). 1989 May;37(5):346-9.
2
In vitro susceptibility of Mycobacterium fortuitum, Mycobacterium chelonae and Mycobacterium avium against some quinolones.偶然分枝杆菌、龟分枝杆菌和鸟分枝杆菌对某些喹诺酮类药物的体外敏感性。
Chemioterapia. 1987 Dec;6(6):431-3.
3
In vitro activity of four fluoroquinolones against eighty-six isolates of mycobacteria.四种氟喹诺酮类药物对86株分枝杆菌的体外活性
Eur J Clin Microbiol. 1987 Oct;6(5):584-6. doi: 10.1007/BF02014255.
4
[Sensitivity of 7 mycobacterial species to new quinolones].[7种分枝杆菌对新型喹诺酮类药物的敏感性]
Pathol Biol (Paris). 1988 May;36(5):477-81.
5
Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.环丙沙星及其他氟喹诺酮类药物对分枝杆菌的活性。
Am J Med. 1987 Apr 27;82(4A):23-6.
6
[Comparison of in vitro antimicrobial activities of ofloxacin, levofloxacin, ciprofloxacin, and sparfloxacin against various mycobacteria].氧氟沙星、左氧氟沙星、环丙沙星和司帕沙星对各种分枝杆菌的体外抗菌活性比较
Kekkaku. 2001 Apr;76(4):357-62.
7
[In vitro antimycobacterial activity of a new quinolone, NM394].[新型喹诺酮类药物NM394的体外抗分枝杆菌活性]
Kekkaku. 1993 Aug;68(8):517-20.
8
[In vitro antimycobacterial activity of a new quinolone, T-3761].[新型喹诺酮类药物T-3761的体外抗分枝杆菌活性]
Kekkaku. 1995 Feb;70(2):97-101.
9
[Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
Rev Med Chir Soc Med Nat Iasi. 2005 Apr-Jun;109(2):383-6.
10
Determination of the susceptibility in vitro of 54 isolates of Mycobacterium fortuitum against three fluoroquinolones using two methods.
J Chemother. 1995 Apr;7(2):109-13. doi: 10.1179/joc.1995.7.2.109.

引用本文的文献

1
The impact of therapeutic-dose induced intestinal enrofloxacin concentrations in healthy pigs on fecal Escherichia coli populations.治疗剂量诱导的健康猪肠道恩诺沙星浓度对粪便大肠杆菌种群的影响。
BMC Vet Res. 2020 Oct 8;16(1):382. doi: 10.1186/s12917-020-02608-9.
2
Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.堪萨斯分枝杆菌对氧氟沙星、司帕沙星、克拉霉素、阿奇霉素和夫西地酸的敏感性。
Antimicrob Agents Chemother. 1993 Sep;37(9):1997-9. doi: 10.1128/AAC.37.9.1997.